The standardized diagnosis and treatment project was launched, and GSK joined hands with various parties to improve the standard diagnosis and treatment and management of lupus

On November 6, 2022, the " The "Standardized Diagnosis and Treatment of Systemic Lupus Erythematosus" project signed a memorandum
of strategic cooperation during the 5th CIIE.
The project will improve the diagnosis and management of lupus through the development and implementation of uniform standards to achieve earlier and better disease management and improve the overall quality of life of
patients.

The strategic cooperation memorandum of understanding of the project "Standardized diagnosis and treatment of systemic lupus erythematosus" was successfully signed

The project plans to publish the Guidelines for the Construction, Management and Quality Control of Chinese Lupus Centers in 2023, and establish 10 lupus demonstration centers and 50 lupus certification centers nationwide.
At the same time, with the help of mutual visits and exchange meetings between hospitals, lupus center certification and other forms, the area is continuously expanded and sinking, forming a coverage network from point to area, so as to improve the overall diagnosis and treatment level
of lupus in China.

"With the development of science and technology, the development of new drugs, including biologics, has advanced by leaps and bounds, which has revolutionized the treatment of lupus
.
However, the level of diagnosis and treatment of medical institutions at all levels is uneven, the rheumatology and immunology departments are vacant in various places, and many grassroots hospitals do not have corresponding departments, which is not conducive to early screening and early diagnosis of diseases, so that patients cannot be effectively managed and treated
.
Professor Zeng Xiaofeng, director of the National Clinical Research Center for Skin and Immune Diseases and director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, said, "At the same time, the concept of standard treatment proposed by grassroots doctors in the "2020 China Diagnosis and Treatment Guidelines for Systemic Lupus Erythematosus" is vague, the prognosis management of patients is not strong, the disease remission rate is low, and the concept of standard treatment proposed by grassroots doctors is vague, the prognosis management of patients is not strong, the disease remission rate is low, and the disease remission rate is low.
The high recurrence rate brings certain challenges
to the long-term standard treatment and standard treatment of the disease.
It is very important
to build a national, systematic and standardized lupus diagnosis and treatment system.
”

Ms.
Wang Dan, Chairman of the China Medical and Health Development Foundation, said: "Since its establishment 17 years ago, the Foundation has always adhered to the national strategy of 'Healthy China', carried out public welfare activities with its own characteristics, and benefited 31 public welfare projects provinces (municipalities directly under the central government), a total of 300 million people benefited
.
The Systematic Lupus Erythematosus Standardized Diagnosis and Treatment Project will help improve the level of diagnosis and management of lupus disease in China by developing and implementing uniform standards, while training and expanding the number of central specialists to promote lupus patient management and patient education
.
The signing of this strategic cooperation memorandum is an important embodiment of the implementation of the national strategic deployment, and it is believed that with the joint efforts of many parties, the project will help more lupus patients get better and earlier treatment and gain a long-term and high-quality life
.
”

Qi Xin, Vice President and General Manager of GSK China, said: "Since 2011, belimumab has been approved in the United States, becoming the world's first treatment for SLE in nearly 60 years GlaxoSmithKline has been deeply involved in the field of lupus for more than ten years, and is committed to enabling more patients to benefit from innovative treatment options earlier and achieve long-term quality survival
.
In 2019, belimumab was approved to enter the Chinese market, and continued to benefit from the 'spillover' effect of the Expo, and new indications have been approved
in the past few years.
We are very pleased to cooperate with foundations, societies, experts and other parties to participate in the project of China Systemic Lupus Erythematosus Diagnosis and Treatment Center, contributing to
the improvement of the diagnosis and treatment and management of lupus disease in China.
”

References

1，J.
Rheumatol 2005, 32(9): 1706-1708.

2，Arthritis Rheum, 2009; 61(9): 1159-67.

3, 2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus, Chinese Journal of Internal Medicine, Vol.
59, No.
3, March 2020 period

4，Yurkovich M, et al.
Arthritis Care Res 2014; 66:608–616;

5，Mok CC, et al.
Arthritis Rheum 2013; 65:2154–2160.

6，Wang Z, Wang Y, Zhu R, et al
。 Medicine, 2015, 94(17).
e794